Fusion Antibodies PLC (AIM:FAB), CEO Adrian Kinkaid presented at the Proactive One2One Investor Conference. The company is diversifying its focus from primarily therapeutics to include diagnostics and research applications of antibodies. Kinkaid emphasised the company's expertise in antibody discovery, engineering, and manufacturing, highlighting its ability to reduce production costs and enhance efficiency.
Key to Fusion Antibodies' strategy are two innovative platforms: 'OptiMAL' and AI/ML (Artificial Intelligence/Machine Learning) based antibody design. 'OptiMAL' offers a highly diverse library of sequences based on the human immune repertoire, providing intact IgG molecules and mammalian cell expression, promising a more reliable manufacturing route. Meanwhile, their AI/ML initiative collaborates with partners and Oxford University to theoretically design antibodies, significantly improving efficiency and specificity in antibody development.
2023 was a challenging year for Fusion Antibodies due to its reliance on VC-funded biotech companies. However, the company has made decisions to reduce costs and position itself for a rebound as market conditions improve. Their expanded focus includes immunodiagnostics and veterinary medicine, aiming to diversify revenue streams and reduce dependency on the volatile biotech sector.
Kinkaid concluded by noting Fusion Antibodies' readiness to collaborate on antibody development and optimisation, underscoring their commitment to innovation and market expansion. This proactive approach in antibody technology and strategic diversification positions Fusion Antibodies as a forward-thinking player in the biotech industry.
